|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1997-4-2
|
|
pubmed:abstractText |
The role and timing of radiotherapy for optimal treatment of localized aggressive non-Hodgkin's lymphoma (NHL) is controversial. We report the long-term results of a single-institution pilot study of alternating chemotherapy (CT) and radiotherapy (RT) in patients with clinical stages I or II tumors exceeding 5 cm.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
925-31
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9006743-Adolescent,
pubmed-meshheading:9006743-Adult,
pubmed-meshheading:9006743-Aged,
pubmed-meshheading:9006743-Aged, 80 and over,
pubmed-meshheading:9006743-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9006743-Combined Modality Therapy,
pubmed-meshheading:9006743-Cyclophosphamide,
pubmed-meshheading:9006743-Doxorubicin,
pubmed-meshheading:9006743-Drug Administration Schedule,
pubmed-meshheading:9006743-Female,
pubmed-meshheading:9006743-Follow-Up Studies,
pubmed-meshheading:9006743-Humans,
pubmed-meshheading:9006743-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9006743-Male,
pubmed-meshheading:9006743-Middle Aged,
pubmed-meshheading:9006743-Neoplasms, Second Primary,
pubmed-meshheading:9006743-Patient Compliance,
pubmed-meshheading:9006743-Pilot Projects,
pubmed-meshheading:9006743-Prednisone,
pubmed-meshheading:9006743-Prognosis,
pubmed-meshheading:9006743-Prospective Studies,
pubmed-meshheading:9006743-Radiotherapy,
pubmed-meshheading:9006743-Teniposide,
pubmed-meshheading:9006743-Time Factors
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin's lymphomas: long-term results for 96 patients with tumors > 5 cm.
|
|
pubmed:affiliation |
Institut Gustave-Roussy, Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
